ArticleJournal for immunotherapy of cancer2026

HFB301001, an OX40-based immunotherapy, drives Treg clearance and CTL activation through optimized OX40 receptor clustering.

Jiliang Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.